We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Test Would Help Cut Bowel Cancer Spread

By LabMedica International staff writers
Posted on 15 Oct 2014
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers.

Lynch syndrome (LS) is an inherited autosomal dominant disorder characterized by an increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the DNA mismatch repair genes. More...


Scientists at the University of Exeter Medical School (UK) and Cardiff University (UK) evaluated the accuracy and cost-effectiveness of strategies to identify LS in newly diagnosed early-onset CRC patients who were less than 50 years of age. Cascade testing of relatives is employed in all strategies for individuals in whom LS was identified. The investigators conducted systematic reviews of the test accuracy of microsatellite instability (MSI) testing or immunohistochemistry (IHC) in individuals with CRC at risk of LS, and of economic evidence relating to diagnostic strategies for LS.

The team identified and assessed 42 studies in total, before constructing a computer model of screening strategies for Lynch Syndrome. These were of mixed quality, with significant methodological concerns identified for most. IHC and MSI can both play a part in diagnosing LS but neither is gold standard. The maximum health benefit to the population of interest would be obtained using universal germline testing, but this would not be cost-effective.

The findings indicate that screening the 1,700 people under the age of 50 who are newly diagnosed with bowel cancer each year would identify two thirds of these whose cancer was caused by Lynch Syndrome. From this group, the findings suggest that 40 further cases of cancer could be avoided in them and their relatives. The team used the same model to estimate that 28 cancer related deaths, 24 from bowel cancer and four from womb cancer, could be prevented each year if Lynch Syndrome screening for people with bowel cancer was introduced.

Ian Frayling, PhD, MRCPath, a senior coauthor, said, “If Lynch Syndrome is identified as the cause of bowel cancer, patients can be offered risk-reducing measures such as more intensive postoperative colonoscopy surveillance to spot recurrences and new cancers early. As close relatives have a 50% chance of sharing the gene, screening would provide a valuable opportunity to detect the condition in children, siblings, parents and more distant relatives. It would mean measures could be taken to reduce the risk of cancers developing.” The study was published in the September 2014 issue of the journal Health Technology Assessment.

Related Links:

University of Exeter Medical School 
Cardiff University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Urine Analyzer
respons® UDS100
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.